Bristol-Myers Squibb to Present New Data for Opdivo (nivolumab) in Advanced...
(Source: Bristol-Myers Squibb Company) PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced results of new clinical research of its Immuno-Oncology agents - Opdivo...
View ArticleHorizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of...
DUBLIN, IRELAND--(Marketwired - Nov 13, 2015) - Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
View ArticleDangerous liaison: Bacteria, viruses in league (Stanford School of Medicine)
(Source: Stanford School of Medicine) Like all viruses, a phage can reproduce itself only by climbing into a cell - in this case, a bacterial cell - and commandeering its replicative machinery. Usually...
View ArticleU.S. FDA Approves New Indications for Harvoni®, Gilead's Once-Daily Single...
– Label Expanded to Include Patients with Genotypes 4, 5 and 6 and Patients Co-Infected with HIV – – Use of Harvoni in Combination with Ribavirin for 12 Weeks Can be Considered for...
View ArticleSuperSonic Imagine to Showcase Its Non-Invasive, 60-Second Liver Assessment...
AIX-EN-PROVENCE, FRANCE--(Marketwired - Nov 12, 2015) - SuperSonic Imagine (EURONEXT PARIS: SSI) (FR0010526814), the highly innovative ultrasound company, announced today that the clinical benefits of...
View ArticleGlobal Hepatitis B Therapeutics in Major Developed Markets 2015-2021 -...
DUBLIN, Nov. 12, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/cjh63c/hepatitis_b) has announced the addition of the "Hepatitis B Therapeutics in Major Developed...
View ArticleStudy Shows Merck Hepatitis C Drug Cures Addicts
Hepatitis C patients who use intravenous drugs were cured at a high rate by Merck & Co.’s experimental therapy, a study found, a result that could put pressure on U.S. states to more broadly cover...
View ArticleAdditional Efficacy and Safety Data for IMBRUVICA® (Ibrutinib) Submitted to...
HORSHAM, Pa., Nov. 13, 2015 /PRNewswire/ -- Janssen Biotech, Inc. announced a supplemental New Drug Application (sNDA) for IMBRUVICA® (ibrutinib) has been submitted to the U.S. Food and Drug...
View ArticleU.S. FDA Approves New Indications for Harvoni®, Gilead’s Once-Daily Single...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Harvoni® (ledipasvir/sofosbuvir) for expanded...
View ArticleNew Analyses Further Add to the Efficacy and Safety Profile of OFEV®...
RIDGEFIELD, Conn. and WASHINGTON, Nov. 13, 2015 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the presentation of new analyses of OFEV for the treatment of idiopathic...
View ArticleAPNewsBreak: Medicare spending $9B on hepatitis C drugs
WASHINGTON (AP) -- Medicare spending on breakthrough medications for hepatitis C will nearly double this year, passing $9 billion, according to new government figures. That's raising insurance costs...
View ArticleThe Risk of Developing Liver Cancer Even After Being Cured from Hepatitis C...
SAN FRANCISCO, Nov. 15, 2015 /PRNewswire/ -- Hepatocellular carcinoma (HCC) remains one of the cancers growing in frequency and mortality in the United States. Patients with hepatitis C virus (HCV)...
View ArticleIntercept Presents New Data Analyses on Non-Invasive Liver Testing From FLINT...
NEW YORK, Nov. 14, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...
View ArticleIntercept Presents New PBC Data at AASLD 2015
Research Demonstrates Scope of Unmet Need in PBC New Analysis of Phase 3 POISE Study Uses Risk Algorithm to Examine Potential of OCA to Lower Patients' Long-Term Risk of Liver Transplant and...
View ArticleAbbVie Submits IMBRUVICA® (ibrutinib) Phase III Combination Data to U.S. FDA...
NORTH CHICAGO, Ill., Nov. 13, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food...
View ArticleAbbVie Submits IMBRUVICA® (ibrutinib) Phase III Combination Data to U.S. FDA...
(Source: AbbVie Inc) NORTH CHICAGO, Ill., Nov. 13, 2015/PRNewswire / -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that it submitted a supplemental New Drug Application...
View ArticleThis Is Why Hepatitis C Drugs Are So Expensive
Earlier this week, actress Pamela Anderson announced that she's been cured of hepatitis C. She shared the news in a joyful (and racy) Instagram post that proclaimed, "I am CURED,” but also acknowledged...
View ArticleGilead's (GILD) HCV Drug Harvoni's Label Expanded in U.S.
Gilead Sciences, Inc. GILD announced a label expansion for its hepatitis C virus (HCV) infection drug, Harvoni, in the U.S. With the label expansion, Harvoni can now be used for the treatment of...
View ArticleEliminating Barriers to Treatment for Patients with HCV Who Inject Drugs...
SAN FRANCISCO, Nov. 15, 2015 /PRNewswire/ -- Injection drug use is a major risk factor for transmission of hepatitis C virus (HCV). In May 2015, the Centers for Disease Control reported that acute HCV...
View ArticleConatus Pharmaceuticals Announces Selection of Late-Breaking Oral...
SAN DIEGO, Nov. 14, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today that the company's late-breaking oral presentation at The Liver Meeting®, the annual meeting of...
View Article